Publicaciones en colaboración con investigadores/as de Hospital San Pedro (24)

2024

  1. Polyphenols and metabolism: from present knowledge to future challenges

    Journal of Physiology and Biochemistry

2023

  1. Beyond the effects of HIV infection and integrase inhibitors-based therapies on oral bacteriome

    Scientific Reports, Vol. 13, Núm. 1

2022

  1. Impact of HIV infection and integrase strand transfer inhibitors-based treatment on the gut virome

    Scientific Reports, Vol. 12, Núm. 1

  2. Integrase Inhibitors Partially Restore Bacterial Translocation, Inflammation and Gut Permeability Induced by HIV Infection: Impact on Gut Microbiota

    Infectious Diseases and Therapy, Vol. 11, Núm. 4, pp. 1541-1557

  3. Severity of COVID-19 attributable to obesity according to BMI and CUN-BAE

    Semergen, Vol. 48, Núm. 8, pp. 6

2021

  1. ACE Gene Variants Rise the Risk of Severe COVID-19 in Patients With Hypertension, Dyslipidemia or Diabetes: A Spanish Pilot Study

    Frontiers in Endocrinology, Vol. 12

  2. Corrigendum: ACE Gene Variants Rise the Risk of Severe COVID-19 in Patients With Hypertension, Dyslipidemia or Diabetes: A Spanish Pilot Study (Frontiers in Endocrinology, (2021), 12, (688071), 10.3389/fendo.2021.688071)

    Frontiers in Endocrinology

  3. La investigación frente al SARS-COV-2 y la COVID-19 en el Departamento de Enfermedades Infecciosas del Hospital Universitario San Pedro-CIBIR

    Zubía, Núm. 39, pp. 63-73

  4. Response to Letter to the Editor from Abobaker and Darrat: "circulating levels of Calcitonin Gene-Related Peptide Are Lower in COVID-19 Patients"

    Journal of the Endocrine Society

  5. The influence of interferon β–1b on gut microbiota composition in patients with multiple sclerosis

    Neurologia, Vol. 36, Núm. 7, pp. 495-503

2020

  1. Autologous fecal transplantation from a lean state potentiates caloric restriction effects on body weight and adiposity in obese mice

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. Characterization of gut microbiota composition in HIV-infected patients with metabolic syndrome

    Journal of Physiology and Biochemistry, Vol. 75, Núm. 3, pp. 299-309

  2. Short-term effects of direct-acting antiviral agents on inflammation and gut microbiota in hepatitis C-infected patients

    European Journal of Internal Medicine, Vol. 67, pp. 47-58

  3. The oral, genital and gut microbiome in HIV infection

    Microbiome and Metabolome in Diagnosis, Therapy, and other Strategic Applications (Elsevier), pp. 307-323

2018

  1. Agaricus bisporus supplementation reduces high-fat diet-induced body weight gain and fatty liver development

    Journal of Physiology and Biochemistry, Vol. 74, Núm. 4, pp. 635-646

2017

  1. Differential effects of antiretrovirals on microbial translocation and gut microbiota composition of HIV-infected patients

    Journal of the International AIDS Society, Vol. 20, Núm. 1

2015

  1. Gut microbiota: a key player in health and disease. A review focused on obesity

    Journal of Physiology and Biochemistry, Vol. 71, Núm. 3, pp. 509-525

  2. Maraviroc modifica la composición de la microbiota intestinal en un modelo animal de obesidad: Una posible opción terapéutica para prevenir los trastornos metabólicos en pacientes infectados por el VIH

    Revista Espanola de Quimioterapia, Vol. 28, Núm. 4, pp. 200-206

2014

  1. Maraviroc, a CCR5 antagonist, ameliorates the development of hepatic steatosis in a mouse model of non-alcoholic fatty liver disease (NAFLD)

    Journal of Antimicrobial Chemotherapy, Vol. 69, Núm. 7, pp. 1903-1910

2013

  1. Multiple frequency bioimpedance is an adequate tool to assess total and regional fat mass in HIV-positive patients but not to diagnose HIV-associated lipoatrophy: A pilot study

    Journal of the International AIDS Society, Vol. 16